Table 1 Study cohort baseline characteristics (all patients had confirmed COVID-19 pneumonia)
From: Sensitivity of point-of-care IgM and IgG test in critically ill patients with SARS-Cov-2
Overall (n = 99) | Positives (n = 91) | Negatives (n = 8) | Intergroup comparison p value | |
|---|---|---|---|---|
Age (years) | 62.4 ± 13.3 | 63.5 ± 12.5 | 50.7 ± 16.9 | 0.009ǂ |
Woman patient | 34 (34.3%) | 32 (35.2%) | 2 (25.0%) | 0.71Φ |
Body-mass index (kg/m2) | 29.1 ± 5.9 | 29.2 ± 5.8 | 29.1 ± 7.1 | 0.94Μ |
Delay between first symptoms and POCST (days) | 17.9 ± 8.2 | 18.6 ± 7.9 | 10.4 ± 7.8 | 0.006ǂ |
Chronic immunosuppression | 9 (9.1%) | 7 (7.7%) | 2 (25.0%) | 0.15Φ |
Diabetes | 31 (31.3%) | 28 (30.8%) | 3 (37.5%) | 0.70Φ |
Corticosteroid use in the past 14 days | 18 (18.2%) | 16 (17.6%) | 2 (25.0%) | 0.63Φ |
Immunosuppression in the past 14 days | 5 (5.1%) | 5 (5.5%) | 0 (0.0%) | 1.0Φ |
SAPS II at admission | 50.1 ± 23.0 | 51.1 ± 22.4 | 40.4 ± 28.7 | 0.17Μ |
Creatininemia at admission (μmol/L) | 106.4 ± 123.7 | 106.4 ± 128.6 | 107.3 ± 45.8 | 0.047Μ |
Lymphocytes’ count on day of POCST (G/L) | 2.3 ± 8.2 | 2.4 ± 8.5 | 1.0 ± 0.7 | 0.56Μ |
Fibrinogen on day of POCST (g/L) | 5.8 ± 2.8 | 5.8 ± 2.8 | 4.4 ± 1.2 | 0.11Μ |